Randomized Controlled Trial of Quinacrine for the Treatment of HBsAg‐Positive Chronic Hepatitis
Henry C. Bodenheimer, Fenton Schaffner, Salvatore Vernace, Shalom Z. Hirschman, Judith D. Goldberg, Thomas Chalmers – 1 January 1983 – Several drugs which react with DNA decrease hepatitis B viral (HBV) DNA polymerase activity in vitro. Because such an alteration of viral replication, if produced in patients with hepatitis B surface antigen (HBsAg)‐positive chronic hepatitis, may lead to elimination of viral infection, we conducted a controlled trial of the use of the intercalating agent, quinacrine hydrochloride, in treatment of HBsAg‐positive chronic hepatitis.